About the Fund
Investment Criteria
Structure:
$100k to $500k initial investment
Convertible debt or equity
Focus:
Phase I: Health Innovation (Current)
Health Equity, Physician Referral, Physician/Clinical Experience, Patient Experience
Phase 2: Multi-Market Tech (2022)
Education, Finance & Insurance, Supply Chain, Transportation & Mobility, Other
Attributes:
Graduate of a recognized accelerator, and/or previously funded
Humbly confident and experienced management team
Large and growing addressable market
Demonstrated product-market fit
Innovative and defensible tech/IP
Profitable unit economics at scale
Likely exit pathways
Location:
Operations in the broader Mid-Atlantic region
Contact Our Team
Board Members
Monique Adams*
Executive Director, 757 Angels
Chandra Briggman
CEO, Activation Capital
RGF Board Chair
Jim Cheng*
Investor and Exited Entrepreneur
Dave Levin, M.D.*
Chief Medical and Information Officer, Phlow Corp.
Bob Mooney*
Co-Founder / Managing Director, NRV
*Investment Committee
Portfolio Companies
DrugViu is generating the most comprehensive data for autoimmune research by combining medical records with validated patient-reported outcomes, a proprietary autoimmune biorepository and access to patients for clinical research.
Floreo is leveraging the power of Virtual Reality to provide a method of teaching social, behavioral, communication and life skills for individuals with Autism Spectrum Disorder (ASD) and related diagnoses.